Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT450 / ritonavir / ABT-267 and ABT-333 administered together with ribavirin (RBV) in adults with chronic infection with hepatitis C virus (HCV) ) of genotype1, previously treated (SAPPHIRE II)
Code
M13-098//2012-002035-29
Promoter
Abbott GmbH & Co. KG
Pathology and candidate patients
Hepatitis
Medical equipment
Dr. Moises Diago
Hospital Quirónsalud Valencia.
Study status
Active
Test product
ABT450 / ritonavir / ABT-267 and ABT-333 administered together with ribavirin (RBV)
Date CEIC
June 11, 2013
CEIC
Hospital Quirónsalud valencia
Contact
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: info.valencia@quironsalud.es
